Eraxis Side Effects
Generic name: anidulafungin
Note: This document contains side effect information about anidulafungin. Some of the dosage forms listed on this page may not apply to the brand name Eraxis.
Some side effects of Eraxis may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to anidulafungin: intravenous powder for solution
Along with its needed effects, anidulafungin (the active ingredient contained in Eraxis) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking anidulafungin:Less common
- Black, tarry stools
- decreased urine
- dry mouth
- increased thirst
- irregular heartbeat
- loss of appetite
- lower back or side pain
- mood or mental changes
- muscle pain or cramps
- nausea or vomiting
- numbness or tingling in the hands, feet or lips
- painful or difficult urination
- pale skin
- shortness of breath
- sore throat
- sores, ulcers, or white spots on the lips or in the mouth
- unusual bleeding or bruising
- unusual tiredness or weakness
- Abdominal or stomach pain
- back pain
- bleeding gums
- blood in the urine or stools
- bloody stools
- bluish color of skin
- blurred or loss of vision
- changes in skin color
- chest pain
- chest tightness
- clay-colored stools
- dark urine
- dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
- extra heartbeats
- fast heartbeat
- flushed, dry skin
- fruit-like breath odor
- hives or welts
- incoherent speech
- increased hunger
- increased urination
- irregular fast heartbeat
- large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
- light-colored stools
- metallic taste
- muscle spasms (tetany) or twitching
- muscle weakness
- pain, redness, or swelling in the arm or leg
- pain, tenderness, and swelling of foot or leg
- pinpoint red spots on the skin
- pounding in the ears
- redness of the skin
- skin rash
- slow heartbeat
- sore mouth or tongue
- swelling of the feet or lower legs
- swollen glands
- trouble breathing
- unexplained weight loss
- unpleasant breath odor
- unusually warm skin
- vomiting of blood
- weight loss
- white patches in the mouth or throat or on the tongue
- white patches with diaper rash
- yellow eyes or skin
Some side effects of anidulafungin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:Rare
- Acid or sour stomach
- bloating or swelling of the face, arms, hands, lower legs, or feet
- disturbed color perception
- double vision
- eye pain
- feeling of warmth
- feeling unusually cold
- halos around light
- loss of bowel control
- night blindness
- over bright appearance of lights
- rapid weight gain
- redness of the face, neck, arms, and occasionally, upper chest
- stomach discomfort or upset
- tingling of the hands or feet
- tunnel vision
- unusual weight gain or loss
- upper stomach pain
For Healthcare Professionals
Applies to anidulafungin: intravenous powder for injection
The most common side effects reported during studies in patients with candidemia and other Candida infections were hypokalemia, nausea, diarrhea, vomiting, pyrexia, and insomnia. Anidulafungin was discontinued in 11.5% of patients due to side effects. The most common side effects leading to discontinuation of anidulafungin (the active ingredient contained in Eraxis) were multi-organ failure and systemic Candida infection.
The most common side effects reported during a study in patients with esophageal candidiasis were diarrhea, pyrexia, anemia, headache, vomiting, nausea, and dyspepsia. Anidulafungin was discontinued in 9% of patients due to side effects. The most common side effect leading to discontinuation of anidulafungin was maculopapular rash.
Metabolic side effects have included hypokalemia (up to 25%), hypomagnesemia (12%), increased blood alkaline phosphatase (12%), hypoglycemia (7%), hyperglycemia (6%), hyperkalemia (6%), dehydration (6%), increased amylase (less than 2%), increased creatine phosphokinase (less than 2%), increased lipase (less than 2%), decreased potassium (less than 2%), decreased magnesium, hypercalcemia, and hypernatremia.
Gastrointestinal side effects have included nausea (up to 24%), diarrhea (up to 18%), vomiting (up to 18%), constipation (8%), dyspepsia (7%), abdominal pain (6%), oral candidiasis (5%), upper abdominal pain, and fecal incontinence.
To reduce occurrence of infusion-related side effects, the rate of infusion should not exceed 1.1 mg/minute.
Other side effects have included pyrexia (up to 18%), bacteremia (18%), peripheral edema (up to 11%), sepsis (7%), chest pain (5%), flushing (less than 2%), hot flushes (less than 2%), infusion-related reaction (less than 2%), rigors (less than 2%), clostridial infection (less than 2%), fungemia, candidiasis, multi-organ failure, and systemic Candida infection. Infusion-related side effects, possibly histamine-mediated, have included rash, urticaria, flushing, pruritus, bronchospasm, dyspnea, and hypotension.
Cardiovascular side effects have included hypotension (15%), hypertension (12%), deep vein thrombosis (10%), phlebitis, and electrocardiogram early transition. Atrial fibrillation, bundle branch block (right), sinus arrhythmia, superficial thrombophlebitis, electrocardiogram QT prolonged, and ventricular extrasystoles have been reported in less than 2% of patients.
Psychiatric side effects have included insomnia (15%), confusional state (8%), and depression (6%).
Genitourinary side effects have included urinary tract infection (15%).
Respiratory side effects have included dyspnea (12%), pleural effusion (10%), cough (up to 7%), pneumonia (6%), and respiratory distress (6%). Bronchospasm has been reported during postmarketing experience.
Hematologic side effects have included anemia (up to 9%), increased white blood cell (8%), thrombocythemia (6%), leukocytosis (5%), coagulopathy (less than 2%), thrombocytopenia (less than 2%), prothrombin time prolonged (less than 2%), neutropenia, leukopenia, and increased and decreased platelet count.
Nervous system side effects have included headache (8%), convulsion (less than 2%), and dizziness (less than 2%).
Hepatic side effects have included increased hepatic enzymes (5%), ALT, and AST. Increased gamma-glutamyltransferase, increased bilirubin, abnormal liver function tests, cholestasis, and hepatic necrosis have been reported in less than 2% of patients. Significant hepatic dysfunction, hepatitis, and hepatic failure have been reported.
Hypersensitivity side effects have included anaphylactic shock and anaphylactic reaction during postmarketing experience.
Dermatologic side effects have included decubitus ulcer (5%), rash, generalized pruritus, and maculopapular rash. Erythema, pruritus, increased sweating, urticaria, and angioneurotic edema have been reported in less than 2% of patients.
Renal side effects have included increased blood creatinine (5%) and urea (less than 2%).
Musculoskeletal side effects have included back pain (5%).
Ocular side effects have included eye pain, blurred vision, and visual disturbance in less than 2% of patients.
More Eraxis resources
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.